Biotechnology Center

The Tunneling Group was established in June 2014 as an independent research group. The main activity of the group lies on the border of molecular biology and computational chemistry. We are using an advanced theoretical approach to investigate the properties of various enzymes, design biologically active compounds, and help experimentalists in the interpretation of their results.

We are employing molecular dynamic simulations, various bioinformatics tools, and in-house know-how methods to improve the selectivity, activity, and stability of enzymes and explore the structure-function relationship of proteins. Instead of modifying active site residues, we are exploring the role of distant residues which can tune the properties of biocatalysts and optimize their performance. Our rational approach explores the multidimensional space of conformational changes, provides a deep understanding of catalysis events, and results in the design of intelligent libraries of enzyme mutants.

We are using knowledge of structural-function relationship as a starting point for optimization of known active compounds, searching for new ones (extensive screening for chemicals that might be used as inhibitors or activators of macromolecules involved in medical or industrial applications), and identification of side targets causing toxicity. We have well-established collaboration with national and international partners from academia, health, and industry.

The experimental part of the Tunneling Group is focused on the production and optimization of proteins and bioactive compounds, and the biochemical and biophysical characterization of enzymes and macromolecules. We have our own high-throughput facility for protein production, purification, binding affinity measurement, and activity testing.

Our research covers three interpenetrating areas including biochemistry and catalysis, health, and environment sectors. Our interests are focused on basic and applicable studies including optimization of enzymes, improvement of their activity and selectivity, development of new drugs (against COVID-19, cancer, cardiovascular and neurodegenerative diseases), antimicrobial peptides and inhibitors (against forest pests), and insight into molecular mechanism standing behind rare diseases and catalysis.

For more information about the Tunneling Group, click on the link below:

http://www.tunnelinggroup.pl/

Group Leader:

Artur Góra, PhD
artur.gora@polsl.pl
tel.: +48 32 237 16 59 
ORCID ID: 0000-0003-2530-6957